Jerusalem, Israel.


The MSK-IMPACT is a large-scale, prospective clinical sequencing initiative using a comprehensive assay in Memorial Sloan Kettering Cancer Center. Through this initiative, tumors from more than 10,000 patients with advanced cancer were sequenced.

The cohort of sequenced tumors encompassed 62 principal tumor types and >300 detailed tumor types, representa­tive of the diversity of patients with metastatic solid cancer treated at MSKCC.

Covering more than 410 genes in the panel, the study detected 78,066 nonsynonymous mutations, out of which 69% were not previously reported in COSMIC cancer database.

Altogether, only 37% of patients harbored at least one actionable alteration and only 11% were subsequently enrolled on a genomically matched clinical trial.

Read the full article at: